Clinical Trial Update: AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen [Phase 2]

View source ↗

Summary

This clinical trial update notes the completion of a Phase 2 study comparing AZD6244 (selumetinib) to pemetrexed in non-small cell lung cancer patients who had …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD6244 (selumetinib)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: AstraZeneca | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED